Literature DB >> 24591578

Revertant mutants modify, but do not rescue, the gating defect of the cystic fibrosis mutant G551D-CFTR.

Zhe Xu1, Luísa S Pissarra, Carlos M Farinha, Jia Liu, Zhiwei Cai, Patrick H Thibodeau, Margarida D Amaral, David N Sheppard.   

Abstract

Cystic fibrosis (CF) is caused by dysfunction of the epithelial anion channel cystic fibrosis transmembrane conductance regulator (CFTR). One strategy to restore function to CF mutants is to suppress defects in CFTR processing and function using revertant mutations. Here, we investigate the effects of the revertant mutations G550E and 4RK (the simultaneous disruption of four arginine-framed tripeptides (AFTs): R29K, R516K, R555K and R766K) on the CF mutant G551D, which impairs severely channel gating without altering protein processing and which affects a residue in the same α-helix as G550 and R555. Both G550E and 4RK augmented strongly CFTR-mediated iodide efflux from BHK cells expressing G551D-CFTR. To learn how revertant mutations influence G551D-CFTR function, we studied protein processing and single-channel behaviour. Neither G550E nor 4RK altered the expression and maturation of G551D-CFTR protein. By contrast, both revertants had marked effects on G551D-CFTR channel gating, increasing strongly opening frequency, while 4RK also diminished noticeably the duration of channel openings. Because G551D-CFTR channel gating is ATP independent, we investigated whether revertant mutations restore ATP dependence to G551D-CFTR. Like wild-type CFTR, the activity of 4RK-G551D-CFTR varied with ATP concentration, suggesting that 4RK confers some ATP dependence on the G551D-CFTR channel. Thus, the revertant mutations G550E and 4RK alter the gating pattern and ATP dependence of G551D-CFTR without restoring single-channel activity to wild-type levels. Based on their impact on the CF mutants F508del and G551D, we conclude that G550E and 4RK have direct effects on CFTR structure, but that their action on CFTR processing and channel function is CF mutation specific.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24591578      PMCID: PMC4230770          DOI: 10.1113/jphysiol.2014.271817

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  62 in total

1.  CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains.

Authors:  Paola Vergani; Steve W Lockless; Angus C Nairn; David C Gadsby
Journal:  Nature       Date:  2005-02-24       Impact factor: 49.962

Review 2.  Molecular pharmacology of the CFTR Cl- channel.

Authors:  T C Hwang; D N Sheppard
Journal:  Trends Pharmacol Sci       Date:  1999-11       Impact factor: 14.819

3.  Structure of nucleotide-binding domain 1 of the cystic fibrosis transmembrane conductance regulator.

Authors:  Hal A Lewis; Sean G Buchanan; Stephen K Burley; Kris Conners; Mark Dickey; Michael Dorwart; Richard Fowler; Xia Gao; William B Guggino; Wayne A Hendrickson; John F Hunt; Margaret C Kearins; Don Lorimer; Peter C Maloney; Kai W Post; Kanagalaghatta R Rajashankar; Marc E Rutter; J Michael Sauder; Stephanie Shriver; Patrick H Thibodeau; Philip J Thomas; Marie Zhang; Xun Zhao; Spencer Emtage
Journal:  EMBO J       Date:  2003-12-18       Impact factor: 11.598

4.  A cluster of negative charges at the amino terminal tail of CFTR regulates ATP-dependent channel gating.

Authors:  J Fu; H L Ji; A P Naren; K L Kirk
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

5.  A comparison of 14 antibodies for the biochemical detection of the cystic fibrosis transmembrane conductance regulator protein.

Authors:  Carlos M Farinha; Filipa Mendes; Mónica Roxo-Rosa; Deborah Penque; Margarida D Amaral
Journal:  Mol Cell Probes       Date:  2004-08       Impact factor: 2.365

Review 6.  Control of cystic fibrosis transmembrane conductance regulator membrane trafficking: not just from the endoplasmic reticulum to the Golgi.

Authors:  Carlos M Farinha; Paulo Matos; Margarida D Amaral
Journal:  FEBS J       Date:  2013-07-05       Impact factor: 5.542

7.  Mutations in the nucleotide binding domain 1 signature motif region rescue processing and functional defects of cystic fibrosis transmembrane conductance regulator delta f508.

Authors:  Ana C V DeCarvalho; Lisa J Gansheroff; John L Teem
Journal:  J Biol Chem       Date:  2002-07-10       Impact factor: 5.157

8.  ATP binding to the motor domain from an ABC transporter drives formation of a nucleotide sandwich dimer.

Authors:  Paul C Smith; Nathan Karpowich; Linda Millen; Jonathan E Moody; Jane Rosen; Philip J Thomas; John F Hunt
Journal:  Mol Cell       Date:  2002-07       Impact factor: 17.970

9.  The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70.

Authors:  Carlos M Farinha; Paulo Nogueira; Filipa Mendes; Deborah Penque; Margarida D Amaral
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

10.  On the mechanism of MgATP-dependent gating of CFTR Cl- channels.

Authors:  Paola Vergani; Angus C Nairn; David C Gadsby
Journal:  J Gen Physiol       Date:  2003-01       Impact factor: 4.086

View more
  12 in total

1.  The G551D CFTR chloride channel spurs the development of personalized medicine.

Authors:  Horst Fischer
Journal:  J Physiol       Date:  2014-05-01       Impact factor: 5.182

2.  Synergistic Potentiation of Cystic Fibrosis Transmembrane Conductance Regulator Gating by Two Chemically Distinct Potentiators, Ivacaftor (VX-770) and 5-Nitro-2-(3-Phenylpropylamino) Benzoate.

Authors:  Wen-Ying Lin; Yoshiro Sohma; Tzyh-Chang Hwang
Journal:  Mol Pharmacol       Date:  2016-07-13       Impact factor: 4.436

3.  Deletion of Phenylalanine 508 in the First Nucleotide-binding Domain of the Cystic Fibrosis Transmembrane Conductance Regulator Increases Conformational Exchange and Inhibits Dimerization.

Authors:  P Andrew Chong; Patrick J Farber; Robert M Vernon; Rhea P Hudson; Anthony K Mittermaier; Julie D Forman-Kay
Journal:  J Biol Chem       Date:  2015-07-06       Impact factor: 5.157

4.  CFTR potentiators partially restore channel function to A561E-CFTR, a cystic fibrosis mutant with a similar mechanism of dysfunction as F508del-CFTR.

Authors:  Yiting Wang; Jia Liu; Avgi Loizidou; Luc A Bugeja; Ross Warner; Bethan R Hawley; Zhiwei Cai; Ashley M Toye; David N Sheppard; Hongyu Li
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

5.  Mutation-specific downregulation of CFTR2 variants by gating potentiators.

Authors:  Radu G Avramescu; Yukari Kai; Haijin Xu; Aurélien Bidaud-Meynard; Andrea Schnúr; Saul Frenkiel; Elias Matouk; Guido Veit; Gergely L Lukacs
Journal:  Hum Mol Genet       Date:  2017-12-15       Impact factor: 6.150

6.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

Authors:  Guido Veit; Radu G Avramescu; Doranda Perdomo; Puay-Wah Phuan; Miklos Bagdany; Pirjo M Apaja; Florence Borot; Daniel Szollosi; Yu-Sheng Wu; Walter E Finkbeiner; Tamas Hegedus; Alan S Verkman; Gergely L Lukacs
Journal:  Sci Transl Med       Date:  2014-07-23       Impact factor: 17.956

7.  The CFTR P67L variant reveals a key role for N-terminal lasso helices in channel folding, maturation, and pharmacologic rescue.

Authors:  Carleen Mae Sabusap; Disha Joshi; Luba Simhaev; Kathryn E Oliver; Hanoch Senderowitz; Marcel van Willigen; Ineke Braakman; Andras Rab; Eric J Sorscher; Jeong S Hong
Journal:  J Biol Chem       Date:  2021-03-26       Impact factor: 5.486

Review 8.  On the Corner of Models and Cure: Gene Editing in Cystic Fibrosis.

Authors:  Marjolein Ensinck; Angélique Mottais; Claire Detry; Teresinha Leal; Marianne S Carlon
Journal:  Front Pharmacol       Date:  2021-04-27       Impact factor: 5.810

9.  Two Small Molecules Restore Stability to a Subpopulation of the Cystic Fibrosis Transmembrane Conductance Regulator with the Predominant Disease-causing Mutation.

Authors:  Xin Meng; Yiting Wang; Xiaomeng Wang; Joe A Wrennall; Tracy L Rimington; Hongyu Li; Zhiwei Cai; Robert C Ford; David N Sheppard
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

10.  A single amino acid substitution in CFTR converts ATP to an inhibitory ligand.

Authors:  Wen-Ying Lin; Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2014-09-15       Impact factor: 4.086

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.